Fantastic webinar today! My takeaways:
- $7m cash on hand + $7m to come (proceeds from Manitol sales, R&D Tax refund, and $1m security refund). So fully funded until mid-2025.
- 4 x phase 2 trials fully funded during this time!
- 60% held by institutional investors
- 2 x funds increased their holding from 12 to 20% and 8 to 19% respectively in the recent CR
- Recent CR fully subscribed raised $10m at 2.2c (these companies do much better due diligence than I'm capable of)
- These institutions don't do their Due Diligence just by having a chat! They go in hard and do a lot of work before investing
- The science on the preclinical work on myelofibrosis treatment has been published in Nature -high standard of results required to be able to get into this science publication
- 3 x companies have exited with promising late Phase 2 or Phase 3 data (where SNT will be by end of year/early next year) for prices like $1.7b USD!
- SNT's drug is SHOWN to reduce fibrosis - Phase 2a study should reaffirm & build on already positive results - will really drive interest in the stock
- Study in scar treatment showing amazing results
- Other trials being funded by Parkinsons UK and also MRMF (they don't want to throw away money!)
- In-house products (not licensed) - 10 years in the making - multiple collaborations across the world
It's a thumb's up from me. Very promising 6-12 months!
Add to My Watchlist
What is My Watchlist?
